KRT-232 and TKI Study in Chronic Myeloid Leukemia

NCT04835584 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: KRT-232
DRUG: Dasatinib
DRUG: Nilotinib

Sponsor

Kartos Therapeutics, Inc.